A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis

Exclusion Criteria

• •Any ILAR Juvenile Idiopathic Arthritis (JIA) subtype other than ERA;
• •Psoriasis or a history of psoriasis in the patient or first-degree relative;
• •Presence of Immunoglobulin M (IgM) rheumatoid factor;
• •Presence of systemic JIA;
• •History of inflammatory bowel disease;
• •previous biologic therapy including anti-tumor necrosis factor (anti-TNF) therapy with a potential impact on pediatric ERA;
• •Infection(s) requiring treatment with IV anti-infectives within 30 days prior to Baseline or oral anti-infectives within 14 days prior to Baseline.